drugset
drugset / Trial / NCT05520645

Etomidate Induction in Hysteroscopic Surgery

NCT05520645 ↗

Unknown 200 enrolled Peking University Third Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

This study intends to study the optimal dose induced by etomidate in outpatients undergoing painless hysteroscopic surgery. At present, the dosage in the user manual is 0.1-0.3mg/kg. In clinical use, it is found that 0.1mg/kg often fails to achieve sedative effect, and 0.3mg/kg is prone to muscle twitching. Therefore, three groups of doses of 0.15mg/kg, 0.2mg/kg and 0.25mg/kg are set. It is hoped that this study will provide a basis for clinical evaluation of etomidate in anesthesia induction of hysteroscopic surgery.

Timeline

Start
2022-08-25
Primary completion
2023-09-30
Completion
2023-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Etomidate Small molecule 0.15 mg/kg —
Subject Etomidate Small molecule 0.2 mg/kg —
Subject Etomidate Small molecule 0.25 mg/kg —
Comparator Propofol Small molecule 2 mg/kg —

Indications

No indication recorded.